Skip to main content
Aptamer Sciences Inc logo

Aptamer Sciences Inc — Investor Relations & Filings

Ticker · 291650 ISIN · KR7291650000 KO Manufacturing
Open in API
Filings indexed 230 across all filing types
Latest filing 2024-06-12 M&A Activity
Country KR South Korea
Listing KO 291650

About Aptamer Sciences Inc

https://aptsci.com/en/

Aptamer Sciences Inc. is a clinical-stage biopharmaceutical company specializing in aptamer technology. The company has established a proprietary, integrated platform for the discovery and development of aptamer-based therapeutics and diagnostics. Its primary focus is on oncology, utilizing its Aptamer-Drug Conjugate (ApDC™) platform to create targeted cancer treatments. The lead candidate, AST-201, is an ApDC targeting the GPC3 protein, which is highly expressed in solid tumors such as liver cancer. The company is advancing AST-201 through clinical trials to evaluate its safety and efficacy. The development pipeline also includes other innovative platforms like Aptamer Radioligand Conjugates (ApRC) and Aptamer Immune Stimulator Conjugates (ApIS), aimed at addressing unmet medical needs in hemato-oncology and other areas. Aptamer Sciences leverages its technology to develop novel therapies with the potential for high specificity and efficacy.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
M&A Activity Classification · 1% confidence The document is a short regulatory announcement regarding the setting of a record date for shareholder register closure, specifically for the purpose of identifying shareholders to exercise dissent rights in a small-scale merger. It does not contain the full merger agreement or financial reports, but rather serves as a formal regulatory notice. As it does not fit into specific categories like M&A activity (which would be the merger itself) or dividend notices, it falls under the general regulatory filing category.
2024-06-12 Korean
주요사항보고서(회사합병결정)
M&A Activity Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange, specifically detailing a 'Company Merger Decision' (회사합병 결정) between Aptamer Sciences and its subsidiary, International Scientific Standards. It provides comprehensive details on the merger method, purpose, financial impact, and timeline. This falls under the category of M&A activity.
2024-06-11 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Aptamer Sciences Inc' (주식회사 압타머사이언스) covering the period from 2024.01.01 to 2024.03.31. It contains detailed financial statements, management discussion and analysis, and business operations information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-16 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official report of the results of an Annual General Meeting (AGM) for Aptamer Sciences, dated 2024-03-28. It details the approval of financial statements, election of directors and auditors, and other resolutions passed during the meeting. This fits the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA) as it provides the official outcome of shareholder votes at a general meeting.
2024-03-28 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment or dismissal of an outside director (사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고). This type of filing specifically concerns changes in the composition of the board of directors, which falls under the 'Board/Management Information' category.
2024-03-28 Korean
사업보고서 (2023.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for Aptamer Science Inc. for the fiscal year 2023. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. It is not an Annual Report (10-K) as it focuses specifically on the audit and financial statements rather than the broader business activity report, and it is not an announcement (RPA) because it contains the full financial data. FY 2023
2024-03-20 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.